Eagle Pharmaceuticals, Inc. (EGRX)

Eagle Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Cash & Equivalents	15.35	55.32	97.66	103.16	109.78	78.79
Cash & Cash Equivalents	15.35	55.32	97.66	103.16	109.78	78.79
Cash Growth	-58.01%	-43.35%	-5.33%	-6.03%	39.32%	-31.28%
Receivables	115.14	72.44	41.15	51.12	48	66.49
Inventory	42.48	47.79	21.91	8.08	6.57	8.3
Other Current Assets	14.27	13.2	11.89	3.72	15.1	10.26
Total Current Assets	187.25	188.75	172.61	166.07	179.45	163.84
Property, Plant & Equipment	1.01	1.17	1.64	2.08	2.2	2.4
Goodwill and Intangibles	152.44	163.36	50.41	52.66	55.33	57.85
Other Long-Term Assets	64.12	52.88	29.08	32.39	17.58	14.52
Total Long-Term Assets	217.57	217.41	81.13	87.13	75.11	74.76
Total Assets	404.82	406.16	253.73	253.19	254.55	238.6
Accounts Payable	15.84	18.99	16.43	6.27	5.46	9.92
Current Debt	8.3	6.25	25.61	8	5	6.25
Other Current Liabilities	62.49	85.84	32.34	23.82	28.36	23.52
Total Current Liabilities	86.63	111.09	74.38	38.09	38.82	39.69
Long-Term Debt	61.9	56.22	0	25.14	33.56	38.16
Other Long-Term Liabilities	4.26	5.3	2.9	3.96	3	0
Total Long-Term Liabilities	66.15	61.51	2.9	29.09	36.56	38.16
Total Liabilities	152.78	172.6	77.28	67.18	75.38	77.84
Total Debt	70.19	62.47	25.61	33.14	38.56	44.41
Debt Growth	40.78%	143.94%	-22.72%	-14.06%	-13.17%	-7.06%
Retained Earnings	122.42	111.5	75.86	84.49	72.5	58.19
Comprehensive Income	-1.11	-1.11	-0.09	0	0	0
Shareholders' Equity	252.04	233.56	176.45	186.01	179.17	160.76
Net Cash / Debt	-54.84	-7.15	72.05	70.02	71.22	34.39
Net Cash / Debt Growth	-	-	2.90%	-1.68%	107.11%	-48.58%
Net Cash Per Share	-4.17	-0.55	5.52	5.08	5.04	2.25
Working Capital	100.62	77.67	98.23	127.98	140.63	124.16
Book Value Per Share	19.25	18.06	13.52	13.80	13.03	10.88

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).